Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease

Authors:

Abstract
No abstract available
Funding Information
  • GlaxoSmithKline Biologicals SA
  • GlaxoSmithKline Biologicals SA